Integrative approach for the analysis of the proteome-wide response to bismuth drugs in: Helicobacter pylori

Yuchuan Wang, Ligang Hu, Feng Xu, Quan Quan, Yau Tsz Lai, Wei Xia, Ya Yang, Yuen Yan Chang, Xinming Yang, Zhifang Chai, Junwen Wang, Ivan K. Chu, Hongyan Li, Hongzhe Sun

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Bismuth drugs, despite being clinically used for decades, surprisingly remain in use and effective for the treatment of Helicobacter pylori infection, even for resistant strains when co-administrated with antibiotics. However, the molecular mechanisms underlying the clinically sustained susceptibility of H. pylori to bismuth drugs remain elusive. Herein, we report that integration of in-house metalloproteomics and quantitative proteomics allows comprehensive uncovering of the bismuth-associated proteomes, including 63 bismuth-binding and 119 bismuth-regulated proteins from Helicobacter pylori, with over 60% being annotated with catalytic functions. Through bioinformatics analysis in combination with bioassays, we demonstrated that bismuth drugs disrupted multiple essential pathways in the pathogen, including ROS defence and pH buffering, by binding and functional perturbation of a number of key enzymes. Moreover, we discovered that HpDnaK may serve as a new target of bismuth drugs to inhibit bacterium-host cell adhesion. The integrative approach we report, herein, provides a novel strategy to unveil the molecular mechanisms of antimicrobial metals against pathogens in general. This study sheds light on the design of new types of antimicrobial agents with multiple targets to tackle the current crisis of antimicrobial resistance.

Original languageEnglish (US)
Pages (from-to)4626-4633
Number of pages8
JournalChemical Science
Volume8
Issue number6
DOIs
StatePublished - 2017

Fingerprint

Bismuth
Proteome
Pharmaceutical Preparations
Pathogens
Bioassay
Cell adhesion
Bioinformatics
Anti-Infective Agents
Bacteria
Metals
Anti-Bacterial Agents
Enzymes

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Integrative approach for the analysis of the proteome-wide response to bismuth drugs in : Helicobacter pylori. / Wang, Yuchuan; Hu, Ligang; Xu, Feng; Quan, Quan; Lai, Yau Tsz; Xia, Wei; Yang, Ya; Chang, Yuen Yan; Yang, Xinming; Chai, Zhifang; Wang, Junwen; Chu, Ivan K.; Li, Hongyan; Sun, Hongzhe.

In: Chemical Science, Vol. 8, No. 6, 2017, p. 4626-4633.

Research output: Contribution to journalArticle

Wang, Y, Hu, L, Xu, F, Quan, Q, Lai, YT, Xia, W, Yang, Y, Chang, YY, Yang, X, Chai, Z, Wang, J, Chu, IK, Li, H & Sun, H 2017, 'Integrative approach for the analysis of the proteome-wide response to bismuth drugs in: Helicobacter pylori', Chemical Science, vol. 8, no. 6, pp. 4626-4633. https://doi.org/10.1039/c7sc00766c
Wang, Yuchuan ; Hu, Ligang ; Xu, Feng ; Quan, Quan ; Lai, Yau Tsz ; Xia, Wei ; Yang, Ya ; Chang, Yuen Yan ; Yang, Xinming ; Chai, Zhifang ; Wang, Junwen ; Chu, Ivan K. ; Li, Hongyan ; Sun, Hongzhe. / Integrative approach for the analysis of the proteome-wide response to bismuth drugs in : Helicobacter pylori. In: Chemical Science. 2017 ; Vol. 8, No. 6. pp. 4626-4633.
@article{61769fd0d93048a8842e1e905fb99f7d,
title = "Integrative approach for the analysis of the proteome-wide response to bismuth drugs in: Helicobacter pylori",
abstract = "Bismuth drugs, despite being clinically used for decades, surprisingly remain in use and effective for the treatment of Helicobacter pylori infection, even for resistant strains when co-administrated with antibiotics. However, the molecular mechanisms underlying the clinically sustained susceptibility of H. pylori to bismuth drugs remain elusive. Herein, we report that integration of in-house metalloproteomics and quantitative proteomics allows comprehensive uncovering of the bismuth-associated proteomes, including 63 bismuth-binding and 119 bismuth-regulated proteins from Helicobacter pylori, with over 60{\%} being annotated with catalytic functions. Through bioinformatics analysis in combination with bioassays, we demonstrated that bismuth drugs disrupted multiple essential pathways in the pathogen, including ROS defence and pH buffering, by binding and functional perturbation of a number of key enzymes. Moreover, we discovered that HpDnaK may serve as a new target of bismuth drugs to inhibit bacterium-host cell adhesion. The integrative approach we report, herein, provides a novel strategy to unveil the molecular mechanisms of antimicrobial metals against pathogens in general. This study sheds light on the design of new types of antimicrobial agents with multiple targets to tackle the current crisis of antimicrobial resistance.",
author = "Yuchuan Wang and Ligang Hu and Feng Xu and Quan Quan and Lai, {Yau Tsz} and Wei Xia and Ya Yang and Chang, {Yuen Yan} and Xinming Yang and Zhifang Chai and Junwen Wang and Chu, {Ivan K.} and Hongyan Li and Hongzhe Sun",
year = "2017",
doi = "10.1039/c7sc00766c",
language = "English (US)",
volume = "8",
pages = "4626--4633",
journal = "Chemical Science",
issn = "2041-6520",
publisher = "Royal Society of Chemistry",
number = "6",

}

TY - JOUR

T1 - Integrative approach for the analysis of the proteome-wide response to bismuth drugs in

T2 - Helicobacter pylori

AU - Wang, Yuchuan

AU - Hu, Ligang

AU - Xu, Feng

AU - Quan, Quan

AU - Lai, Yau Tsz

AU - Xia, Wei

AU - Yang, Ya

AU - Chang, Yuen Yan

AU - Yang, Xinming

AU - Chai, Zhifang

AU - Wang, Junwen

AU - Chu, Ivan K.

AU - Li, Hongyan

AU - Sun, Hongzhe

PY - 2017

Y1 - 2017

N2 - Bismuth drugs, despite being clinically used for decades, surprisingly remain in use and effective for the treatment of Helicobacter pylori infection, even for resistant strains when co-administrated with antibiotics. However, the molecular mechanisms underlying the clinically sustained susceptibility of H. pylori to bismuth drugs remain elusive. Herein, we report that integration of in-house metalloproteomics and quantitative proteomics allows comprehensive uncovering of the bismuth-associated proteomes, including 63 bismuth-binding and 119 bismuth-regulated proteins from Helicobacter pylori, with over 60% being annotated with catalytic functions. Through bioinformatics analysis in combination with bioassays, we demonstrated that bismuth drugs disrupted multiple essential pathways in the pathogen, including ROS defence and pH buffering, by binding and functional perturbation of a number of key enzymes. Moreover, we discovered that HpDnaK may serve as a new target of bismuth drugs to inhibit bacterium-host cell adhesion. The integrative approach we report, herein, provides a novel strategy to unveil the molecular mechanisms of antimicrobial metals against pathogens in general. This study sheds light on the design of new types of antimicrobial agents with multiple targets to tackle the current crisis of antimicrobial resistance.

AB - Bismuth drugs, despite being clinically used for decades, surprisingly remain in use and effective for the treatment of Helicobacter pylori infection, even for resistant strains when co-administrated with antibiotics. However, the molecular mechanisms underlying the clinically sustained susceptibility of H. pylori to bismuth drugs remain elusive. Herein, we report that integration of in-house metalloproteomics and quantitative proteomics allows comprehensive uncovering of the bismuth-associated proteomes, including 63 bismuth-binding and 119 bismuth-regulated proteins from Helicobacter pylori, with over 60% being annotated with catalytic functions. Through bioinformatics analysis in combination with bioassays, we demonstrated that bismuth drugs disrupted multiple essential pathways in the pathogen, including ROS defence and pH buffering, by binding and functional perturbation of a number of key enzymes. Moreover, we discovered that HpDnaK may serve as a new target of bismuth drugs to inhibit bacterium-host cell adhesion. The integrative approach we report, herein, provides a novel strategy to unveil the molecular mechanisms of antimicrobial metals against pathogens in general. This study sheds light on the design of new types of antimicrobial agents with multiple targets to tackle the current crisis of antimicrobial resistance.

UR - http://www.scopus.com/inward/record.url?scp=85021765584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021765584&partnerID=8YFLogxK

U2 - 10.1039/c7sc00766c

DO - 10.1039/c7sc00766c

M3 - Article

AN - SCOPUS:85021765584

VL - 8

SP - 4626

EP - 4633

JO - Chemical Science

JF - Chemical Science

SN - 2041-6520

IS - 6

ER -